Stefani Wolff - Apr 30, 2023 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role: EVP and COO
Signature: /s/ Christine Ring, as Attorney-in-Fact for Stefani Wolff
Stock symbol: NRIX
Transactions as of: Apr 30, 2023
Transactions value $: -$3,378
Form type: 4
Date filed: 5/2/2023, 04:33 PM
Previous filing: Feb 15, 2023
Next filing: Aug 11, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NRIX	Common Stock	Options Exercise	$0	+962	+17.51%	$0.00	6.46K	Apr 30, 2023	Direct	F1
transaction	NRIX	Common Stock	Sale	-$3.38K	-342	-5.3%	$9.88	6.11K	May 1, 2023	Direct	F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NRIX	Restricted Stock Units	Options Exercise	$0	-962	-8.33%	$0.00	10.6K	Apr 30, 2023	Common Stock	962	$0.00	Direct	F4, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Stefani Wolff is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Includes 1,553 shares of Common Stock acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's employee stock purchase plan.
F2	The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3	Represents the weighted average sale price. The lowest price at which shares were sold was $9.82 and the highest price at which shares were sold was $9.94. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F4	Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5	The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F6	RSUs do not expire; they either vest or are canceled prior to the vest date.